PDS Biotech Narrows Loss, Cash Drains Amid R&D Cuts

TL;DR

**PDSB is burning through cash and diluting shareholders to stay afloat, with no commercial products in sight – a risky bet on future clinical success.**

AI Summary

PDS Biotechnology Corp (PDSB) reported a net loss of $17,923,175 for the six months ended June 30, 2025, a slight improvement from the $18,931,374 net loss in the prior-year period. Revenue remains non-existent as the company is clinical-stage. Research and development expenses decreased by 10.5% to $10,043,918 for the six months ended June 30, 2025, down from $11,231,862 in the same period of 2024. General and administrative expenses also saw a reduction, falling 11.4% to $6,685,191 from $7,550,069. Cash and cash equivalents significantly declined to $31,873,495 as of June 30, 2025, from $41,689,591 at December 31, 2024, representing a 23.6% decrease. The company raised capital through various financing activities, including $1,009,969 from pre-funded warrants, $2,150,771 from warrants, and $1,766,757 from common stock issuances via a Sales Agreement, alongside $6,994,174 from other common stock issuances, net of costs. Total liabilities decreased to $24,516,281 from $26,353,809, primarily due to a reduction in short-term notes payable from $12,500,000 to $5,500,000. The accumulated deficit grew to $200,034,174, reflecting ongoing operational losses.

Why It Matters

For investors, PDSB's continued net losses and significant cash burn, despite reduced R&D and G&A expenses, signal ongoing financial challenges for this clinical-stage biotech. The company's reliance on equity and warrant issuances for funding, while necessary, dilutes existing shareholder value. Employees and customers are directly impacted by the success of PDSB's immunotherapy pipeline, which remains uncommercialized. In a highly competitive biotech landscape, PDSB's ability to secure further funding and advance its Versamune, PDS01ADC, and Infectimune platforms is critical to its long-term viability and competitive positioning against larger pharmaceutical companies with deeper pockets and more advanced pipelines.

Risk Assessment

Risk Level: high — PDSB reported a net loss of $17,923,175 for the six months ended June 30, 2025, and a cash balance of $31,873,495, down from $41,689,591 at December 31, 2024. The company has an accumulated deficit of $200,034,174 and no commercially approved products, indicating a high reliance on future financing and successful clinical trials, which are inherently uncertain.

Analyst Insight

Investors should exercise extreme caution and consider PDSB a highly speculative investment. Monitor the company's cash burn rate closely and look for concrete progress in clinical trials, particularly any data that could attract significant partnership or acquisition interest, as continued dilution is likely without a major catalyst.

Financial Highlights

debt To Equity

1.54

revenue

$0

operating Margin

N/A

total Assets

$40.5M

total Debt

$24.5M

net Income

-$17.9M

eps

-$0.41

gross Margin

N/A

cash Position

$31.9M

revenue Growth

N/A

Key Numbers

• $17.9M — Net Loss (for the six months ended June 30, 2025, an improvement from $18.9M in 2024)
• $31.9M — Cash and Cash Equivalents (as of June 30, 2025, down 23.6% from $41.7M at Dec 31, 2024)
• $10.0M — Research and Development Expenses (for the six months ended June 30, 2025, a 10.5% decrease from $11.2M in 2024)
• $6.7M — General and Administrative Expenses (for the six months ended June 30, 2025, an 11.4% decrease from $7.6M in 2024)
• $200.0M — Accumulated Deficit (as of June 30, 2025, indicating significant historical losses)
• 46,633,362 — Common Shares Outstanding (as of August 6, 2025, up from 37,987,380 at Dec 31, 2024, indicating dilution)
• $1.0M — Proceeds from Pre-funded Warrants (for the six months ended June 30, 2025, a financing activity)
• $2.2M — Proceeds from Warrants (for the six months ended June 30, 2025, a financing activity)
• $1.8M — Proceeds from Sales Agreement (for the six months ended June 30, 2025, from common stock issuance)
• $7.0M — Proceeds from Common Stock (for the six months ended June 30, 2025, net of issuance costs)

Key Players & Entities

• PDS Biotechnology Corp (company) — registrant
• SEC (regulator) — filing oversight
• Nasdaq Stock Market LLC (company) — exchange where PDSB is listed
• Versamune (company) — proprietary immunotherapy platform
• PDS01ADC (company) — investigational tumor-targeting fusion protein
• Infectimune (company) — immunotherapy platform for infectious diseases
• FASB (regulator) — accounting standards setter
• ASC 718 (regulator) — accounting standard for stock-based compensation
• ASC 842 (regulator) — accounting standard for leases
• ASU 2023-07 (regulator) — new accounting standard for segment reporting

FAQ

Risk Factors

• Significant Cash Burn and Need for Future Financing [high — financial]: The company's cash and cash equivalents decreased by 23.6% to $31.9 million as of June 30, 2025, from $41.7 million at December 31, 2024. This substantial burn rate, coupled with an accumulated deficit of $200.0 million, indicates a continued reliance on external financing to fund operations and development activities.
• Dilution from Equity Issuances [medium — financial]: PDSB has actively raised capital through the issuance of common stock, pre-funded warrants, and warrants, resulting in an increase in common shares outstanding from 37.9 million at December 31, 2024, to 46.6 million at August 6, 2025. This significant dilution can negatively impact existing shareholders' ownership percentage and potentially the stock price.
• Clinical-Stage Development Risks [high — operational]: As a clinical-stage biotechnology company, PDSB faces inherent risks associated with drug development, including the possibility of clinical trial failures, regulatory hurdles, and the long, expensive process of bringing a product to market. The absence of revenue underscores the speculative nature of the company's business model.
• Increasing Interest Expense [medium — financial]: Interest expense has increased significantly, rising from $1.2 million for the six months ended June 30, 2024, to $3.1 million for the same period in 2025. This increase is likely due to higher debt levels or increased interest rates on existing debt, impacting overall profitability.
• Dependence on Regulatory Approvals [high — regulatory]: The success of PDSB is contingent upon obtaining regulatory approvals for its drug candidates from agencies like the FDA. Delays or rejections in the approval process can severely impact the company's timeline, financial projections, and overall viability.

Industry Context

PDS Biotechnology operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel immunotherapies. The industry is characterized by long development cycles, high failure rates in clinical trials, and significant regulatory oversight. Success hinges on innovation, robust clinical data, and effective capital management to navigate the path from research to commercialization.

Regulatory Implications

As a clinical-stage biopharmaceutical company, PDSB is subject to stringent regulations by health authorities like the FDA. Any delays or adverse outcomes in clinical trials or the regulatory review process can have profound financial and operational consequences. Compliance with evolving regulatory standards is critical for advancing its product pipeline.

What Investors Should Do

1. Monitor clinical trial progress and data readouts closely for catalysts and potential setbacks.
2. Assess the company's cash runway and future financing needs, considering the potential for further dilution.
3. Evaluate the competitive landscape and PDSB's differentiation in its therapeutic areas.
4. Analyze the increasing interest expense and its impact on the company's path to profitability.
5. Consider the long-term viability and risk profile associated with investing in a clinical-stage biotechnology company.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any accumulated profits. It represents the total losses that have not been offset by profits. (PDSB's accumulated deficit of $200.0 million highlights its history of operating losses as a clinical-stage company.)

Clinical-Stage Company

A biotechnology or pharmaceutical company that is primarily focused on the research and development of new drugs or therapies, but has not yet received regulatory approval to market its products. (This classification explains why PDSB has no revenue and incurs significant R&D expenses.)

Pre-funded Warrants

A type of warrant that allows the holder to purchase shares of common stock at a nominal exercise price, often used in financing rounds to provide immediate capital while deferring full equity dilution. (PDSB raised $1.0 million from pre-funded warrants, indicating a financing strategy to secure funds.)

Sales Agreement

A contract between a company and an agent (often an investment bank) to sell shares of the company's stock in the open market over a period of time. (PDSB utilized a sales agreement to raise $1.8 million through common stock issuances.)

Dilution

The reduction in the ownership percentage of a shareholder when a company issues new shares, which can decrease the earnings per share and voting power. (The increase in common shares outstanding from 37.9 million to 46.6 million indicates significant dilution for existing shareholders.)

Year-Over-Year Comparison

Compared to the prior-year period, PDS Biotechnology has reduced its net loss for the six months ended June 30, 2025, to $17.9 million from $18.9 million. Operating expenses, specifically R&D and G&A, have also decreased by 10.5% and 11.4%, respectively. However, cash reserves have significantly declined by 23.6%, and interest expenses have more than doubled, indicating increased financial leverage and a continued need for capital infusion despite cost-saving measures.

Key Financial Figures

• $0.00033 — ich registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Stock Mar

Filing Documents

• ef20050390_10q.htm (10-Q) — 1214KB
• ef20050390_ex10-2.htm (EX-10.2) — 17KB
• ef20050390_ex10-7.htm (EX-10.7) — 64KB
• ef20050390_ex31-1.htm (EX-31.1) — 15KB
• ef20050390_ex31-2.htm (EX-31.2) — 14KB
• ef20050390_ex32-1.htm (EX-32.1) — 6KB
• ef20050390_ex32-2.htm (EX-32.2) — 6KB
• image01.jpg (GRAPHIC) — 1600KB
• 0001140361-25-030825.txt ( ) — 9346KB
• pdsb-20250630.xsd (EX-101.SCH) — 35KB
• pdsb-20250630_cal.xml (EX-101.CAL) — 40KB
• pdsb-20250630_def.xml (EX-101.DEF) — 138KB
• pdsb-20250630_lab.xml (EX-101.LAB) — 478KB
• pdsb-20250630_pre.xml (EX-101.PRE) — 265KB
• ef20050390_10q_htm.xml (XML) — 721KB

— Financial Information

Part I — Financial Information Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited): Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations and Comprehensive Loss 4 Condensed Consolidated Statements of Changes in Stockholders' Equity 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31

— Other Information

Part II — Other Information 32 Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 3. Defaults Upon Senior Securities 35 Item 4. Mine Safety Disclosures 35 Item 5. Other Information 35 Item 6. Exhibits 36 EXHIBIT INDEX 36

SIGNATURES

SIGNATURES 37 Index PART 1. FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY Condensed Consolidated Balance Sheets June 30, 2025 December 31, 2024 ASSETS (unaudited) Current assets: Cash and cash equivalents $ 31,873,495 $ 41,689,591 Prepaid expenses and other assets 1,774,550 3,364,852 Total current assets 33,648,045 45,054,443 Noncurrent assets: Prepaid expenses 6,554,064 - Property and equipment, net 131,102 142,020 Financing lease right-to-use assets 142,854 162,194 Total assets $ 40,476,065 $ 45,358,657 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 4,497,434 $ 1,684,868 Accrued expenses 1,482,081 2,841,214 Note payable - short term 5,500,000 12,500,000 Financing lease obligation-short term 51,937 61,119 Total current liabilities 11,531,452 17,087,201 Noncurrent liabilities: Note payable, net of debt discount 12,943,656 9,204,755 Financing lease obligation-long term 41,173 61,853 Total liabilities $ 24,516,281 $ 26,353,809 Commitments and contingencies (Note 9) STOCKHOLDERS' EQUITY Common stock, $ 0.00033 par value, 150,000,000 shares authorized at June 30 , 2025 and December 31, 2024 , respectively; 46,633,362 and 37,987,380 issued and outstanding at June 30 , 2025 and December 31, 2024 , respectively 15,390 12,536 Additional paid-in capital 215,978,568 201,103,311 Accumulated deficit ( 200,034,174 ) ( 182,110,999 ) Total stockholders' equity 15,959,784 19,004,848 Total liabilities and stockholders' equity $ 40,476,065 $ 45,358,657 See accompanying notes to the condensed consolidated financial statements. 3 Index PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development expenses $ 4,212,918 $ 4,527,698

View Full Filing

View this 10-Q filing on SEC EDGAR